Semaglutide for Smoking Cessation in Patients With Diabetes

NCT07059377 · Recruiting

Last updated 2026-05-28

This clinical trial is testing whether the medication semaglutide can help people with type 2 diabetes who smoke to quit smoking.

Status Recruiting Currently enrolling participants.

Phase Phase 3 Confirms effectiveness in a large group before approval.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) treatment study

Participants 100 people Planned (estimated).

Who can join Ages 18+ · all sexes

Timeline Started 2026-02 · est. completion 2027-07

Where 1 site · Canada

What this study is testing ClinicalTrials.gov NCT07059377 ↗

Description as written by the study sponsor.

To assess the feasibility of conducting a randomized controlled trial (RCT) to determine the effectiveness of semaglutide as an adjunct to combination NRT in supporting smoking cessation for patients with diabetes.

Treatments tested

Semaglutide Drug

Starting dose will be 0.25mg once a week for 4 weeks, then titrated up to 0.5mg once a week. For those requiring additional blood sugar control, the dose may be titrated up to the maximum dose of 2mg once a week. All participants will use this medication for up to 26 weeks
Nicotine replacement Drug

Nicotine patch plus short-acting NRT gum or lozenge

Main thing measured	Project success
Sponsor	Ottawa Heart Institute Research Corporation
Conditions studied	Diabetes Mellitus, Type 2, Nicotine Addiction, Tobacco Dependence
GLP-1 drugs	semaglutide

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT07059377 ↗